论文信息 - How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 - 字舞流文

How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

G. Trifirò | R. Gini | M. Santarpia | A. Caputi | Y. Ingrasciotta | Ilaria Marcianò | S. Scondotto | F. Giorgianni | A. Genazzani | L. Sottosanti | Sonia Manna | V. Ientile | M. Pastorello | P. Cananzi | G. Traversa | A. Chinellato | Jenny Bolcato | R. Pirolo | I. Uomo | Mariangela Rossi | R. Cas | A. Giorgio | Sebastiano W. Pollina Addario | Valentina Ientile

[1] C. Bokemeyer,et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) , 2016, Supportive Care in Cancer.

[2] G. Trifirò,et al. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 , 2015, BioDrugs.

[3] T. Egberts,et al. Traceability of biologicals: present challenges in pharmacovigilance , 2015, Expert opinion on drug safety.

[4] G. Trifirò,et al. Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database , 2014, Drug Safety.

[5] J. Fuhr,et al. The economics of biosimilars. , 2013, American health & drug benefits.

[6] M. Wadhwa,et al. Biosimilars: what clinicians should know. , 2012, Blood.

[7] Robert Haustein. Saving money in the European healthcare systems with biosimilars , 2012 .

[8] M. Aapro,et al. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9] Richard M. Johnson. Guideline on similar biological medicinal products , 2010 .

[10] G. Biggio,et al. Biosimilar drugs : concerns and opportunities. , 2007, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.